Cargando…
Discontinuation and remission rates and social functioning in patients with schizophrenia receiving second‐generation antipsychotics: 52‐week evaluation of JUMPs, a randomized, open‐label study
AIM: Globally, evidence from short‐term studies is insufficient for the guidelines to uniformly recommend a particular antipsychotic(s) for the maintenance treatment of schizophrenia. Therefore, long‐term comprehensive evaluation of antipsychotics is required from a social rehabilitation perspective...
Autores principales: | , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley & Sons Australia, Ltd
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9299006/ https://www.ncbi.nlm.nih.gov/pubmed/34626144 http://dx.doi.org/10.1111/pcn.13304 |
_version_ | 1784750845226647552 |
---|---|
author | Ishigooka, Jun Nakagome, Kazuyuki Ohmori, Tetsuro Iwata, Nakao Inada, Ken Iga, Jun‐ichi Kishi, Taro Fujita, Kiyoshi Kikuchi, Yuka Shichijo, Toshiaki Tabuse, Hideaki Koretsune, Shotatsu Terada, Hiroshi Terada, Haruko Kishimoto, Toshifumi Tsutsumi, Yuichiro Kanda, Yoshiki Ohi, Kazutaka Sekiyama, Kanji |
author_facet | Ishigooka, Jun Nakagome, Kazuyuki Ohmori, Tetsuro Iwata, Nakao Inada, Ken Iga, Jun‐ichi Kishi, Taro Fujita, Kiyoshi Kikuchi, Yuka Shichijo, Toshiaki Tabuse, Hideaki Koretsune, Shotatsu Terada, Hiroshi Terada, Haruko Kishimoto, Toshifumi Tsutsumi, Yuichiro Kanda, Yoshiki Ohi, Kazutaka Sekiyama, Kanji |
author_sort | Ishigooka, Jun |
collection | PubMed |
description | AIM: Globally, evidence from short‐term studies is insufficient for the guidelines to uniformly recommend a particular antipsychotic(s) for the maintenance treatment of schizophrenia. Therefore, long‐term comprehensive evaluation of antipsychotics is required from a social rehabilitation perspective, especially for drugs that have not yet been studied. The Japan Useful Medication Program for Schizophrenia (JUMPs) is a large‐scale, long‐term naturalistic study to present pivotal 52‐week data on the continuity of second‐generation antipsychotics (SGA: aripiprazole, blonanserin, and paliperidone). METHODS: JUMPs was an open‐label, three‐arm, randomized, parallel‐group, 52‐week study. Enrolled patients had schizophrenia, were ≥20 years old, and required antipsychotic treatment or switched from previous therapy. The primary endpoint was treatment discontinuation rate over 52 weeks. Secondary outcomes included remission rate, social functioning, and quality‐of‐life scores [Personal and Social Performance Scale (PSP) and EuroQol‐5 dimensions], and safety. RESULTS: In total, 251 patients received aripiprazole (n = 82), blonanserin (n = 85), or paliperidone (n = 84). The discontinuation rate (P = 0.9771) and remission rates (P > 0.05) over 52 weeks did not differ significantly between the three treatment groups. The discontinuation rates were 68.3%, 68.2%, and 65.5% in the aripiprazole, blonanserin, and paliperidone groups, respectively. Significant improvements (all P < 0.05) from baseline in PSP scores were observed at start of monotherapy, week 26, and week 52 in the overall cohort and blonanserin group and at week 26 in the aripiprazole group. The adverse event profile favored blonanserin. CONCLUSION: All three SGAs evaluated in this study showed similar treatment discontinuation rates in patients with chronic schizophrenia in Japan. |
format | Online Article Text |
id | pubmed-9299006 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | John Wiley & Sons Australia, Ltd |
record_format | MEDLINE/PubMed |
spelling | pubmed-92990062022-07-21 Discontinuation and remission rates and social functioning in patients with schizophrenia receiving second‐generation antipsychotics: 52‐week evaluation of JUMPs, a randomized, open‐label study Ishigooka, Jun Nakagome, Kazuyuki Ohmori, Tetsuro Iwata, Nakao Inada, Ken Iga, Jun‐ichi Kishi, Taro Fujita, Kiyoshi Kikuchi, Yuka Shichijo, Toshiaki Tabuse, Hideaki Koretsune, Shotatsu Terada, Hiroshi Terada, Haruko Kishimoto, Toshifumi Tsutsumi, Yuichiro Kanda, Yoshiki Ohi, Kazutaka Sekiyama, Kanji Psychiatry Clin Neurosci Regular Article AIM: Globally, evidence from short‐term studies is insufficient for the guidelines to uniformly recommend a particular antipsychotic(s) for the maintenance treatment of schizophrenia. Therefore, long‐term comprehensive evaluation of antipsychotics is required from a social rehabilitation perspective, especially for drugs that have not yet been studied. The Japan Useful Medication Program for Schizophrenia (JUMPs) is a large‐scale, long‐term naturalistic study to present pivotal 52‐week data on the continuity of second‐generation antipsychotics (SGA: aripiprazole, blonanserin, and paliperidone). METHODS: JUMPs was an open‐label, three‐arm, randomized, parallel‐group, 52‐week study. Enrolled patients had schizophrenia, were ≥20 years old, and required antipsychotic treatment or switched from previous therapy. The primary endpoint was treatment discontinuation rate over 52 weeks. Secondary outcomes included remission rate, social functioning, and quality‐of‐life scores [Personal and Social Performance Scale (PSP) and EuroQol‐5 dimensions], and safety. RESULTS: In total, 251 patients received aripiprazole (n = 82), blonanserin (n = 85), or paliperidone (n = 84). The discontinuation rate (P = 0.9771) and remission rates (P > 0.05) over 52 weeks did not differ significantly between the three treatment groups. The discontinuation rates were 68.3%, 68.2%, and 65.5% in the aripiprazole, blonanserin, and paliperidone groups, respectively. Significant improvements (all P < 0.05) from baseline in PSP scores were observed at start of monotherapy, week 26, and week 52 in the overall cohort and blonanserin group and at week 26 in the aripiprazole group. The adverse event profile favored blonanserin. CONCLUSION: All three SGAs evaluated in this study showed similar treatment discontinuation rates in patients with chronic schizophrenia in Japan. John Wiley & Sons Australia, Ltd 2021-11-17 2022-01 /pmc/articles/PMC9299006/ /pubmed/34626144 http://dx.doi.org/10.1111/pcn.13304 Text en © 2021 The Authors. Psychiatry and Clinical Neurosciences published by John Wiley & Sons Australia, Ltd on behalf of Japanese Society of Psychiatry and Neurology. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made. |
spellingShingle | Regular Article Ishigooka, Jun Nakagome, Kazuyuki Ohmori, Tetsuro Iwata, Nakao Inada, Ken Iga, Jun‐ichi Kishi, Taro Fujita, Kiyoshi Kikuchi, Yuka Shichijo, Toshiaki Tabuse, Hideaki Koretsune, Shotatsu Terada, Hiroshi Terada, Haruko Kishimoto, Toshifumi Tsutsumi, Yuichiro Kanda, Yoshiki Ohi, Kazutaka Sekiyama, Kanji Discontinuation and remission rates and social functioning in patients with schizophrenia receiving second‐generation antipsychotics: 52‐week evaluation of JUMPs, a randomized, open‐label study |
title | Discontinuation and remission rates and social functioning in patients with schizophrenia receiving second‐generation antipsychotics: 52‐week evaluation of JUMPs, a randomized, open‐label study |
title_full | Discontinuation and remission rates and social functioning in patients with schizophrenia receiving second‐generation antipsychotics: 52‐week evaluation of JUMPs, a randomized, open‐label study |
title_fullStr | Discontinuation and remission rates and social functioning in patients with schizophrenia receiving second‐generation antipsychotics: 52‐week evaluation of JUMPs, a randomized, open‐label study |
title_full_unstemmed | Discontinuation and remission rates and social functioning in patients with schizophrenia receiving second‐generation antipsychotics: 52‐week evaluation of JUMPs, a randomized, open‐label study |
title_short | Discontinuation and remission rates and social functioning in patients with schizophrenia receiving second‐generation antipsychotics: 52‐week evaluation of JUMPs, a randomized, open‐label study |
title_sort | discontinuation and remission rates and social functioning in patients with schizophrenia receiving second‐generation antipsychotics: 52‐week evaluation of jumps, a randomized, open‐label study |
topic | Regular Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9299006/ https://www.ncbi.nlm.nih.gov/pubmed/34626144 http://dx.doi.org/10.1111/pcn.13304 |
work_keys_str_mv | AT ishigookajun discontinuationandremissionratesandsocialfunctioninginpatientswithschizophreniareceivingsecondgenerationantipsychotics52weekevaluationofjumpsarandomizedopenlabelstudy AT nakagomekazuyuki discontinuationandremissionratesandsocialfunctioninginpatientswithschizophreniareceivingsecondgenerationantipsychotics52weekevaluationofjumpsarandomizedopenlabelstudy AT ohmoritetsuro discontinuationandremissionratesandsocialfunctioninginpatientswithschizophreniareceivingsecondgenerationantipsychotics52weekevaluationofjumpsarandomizedopenlabelstudy AT iwatanakao discontinuationandremissionratesandsocialfunctioninginpatientswithschizophreniareceivingsecondgenerationantipsychotics52weekevaluationofjumpsarandomizedopenlabelstudy AT inadaken discontinuationandremissionratesandsocialfunctioninginpatientswithschizophreniareceivingsecondgenerationantipsychotics52weekevaluationofjumpsarandomizedopenlabelstudy AT igajunichi discontinuationandremissionratesandsocialfunctioninginpatientswithschizophreniareceivingsecondgenerationantipsychotics52weekevaluationofjumpsarandomizedopenlabelstudy AT kishitaro discontinuationandremissionratesandsocialfunctioninginpatientswithschizophreniareceivingsecondgenerationantipsychotics52weekevaluationofjumpsarandomizedopenlabelstudy AT fujitakiyoshi discontinuationandremissionratesandsocialfunctioninginpatientswithschizophreniareceivingsecondgenerationantipsychotics52weekevaluationofjumpsarandomizedopenlabelstudy AT kikuchiyuka discontinuationandremissionratesandsocialfunctioninginpatientswithschizophreniareceivingsecondgenerationantipsychotics52weekevaluationofjumpsarandomizedopenlabelstudy AT shichijotoshiaki discontinuationandremissionratesandsocialfunctioninginpatientswithschizophreniareceivingsecondgenerationantipsychotics52weekevaluationofjumpsarandomizedopenlabelstudy AT tabusehideaki discontinuationandremissionratesandsocialfunctioninginpatientswithschizophreniareceivingsecondgenerationantipsychotics52weekevaluationofjumpsarandomizedopenlabelstudy AT koretsuneshotatsu discontinuationandremissionratesandsocialfunctioninginpatientswithschizophreniareceivingsecondgenerationantipsychotics52weekevaluationofjumpsarandomizedopenlabelstudy AT teradahiroshi discontinuationandremissionratesandsocialfunctioninginpatientswithschizophreniareceivingsecondgenerationantipsychotics52weekevaluationofjumpsarandomizedopenlabelstudy AT teradaharuko discontinuationandremissionratesandsocialfunctioninginpatientswithschizophreniareceivingsecondgenerationantipsychotics52weekevaluationofjumpsarandomizedopenlabelstudy AT kishimototoshifumi discontinuationandremissionratesandsocialfunctioninginpatientswithschizophreniareceivingsecondgenerationantipsychotics52weekevaluationofjumpsarandomizedopenlabelstudy AT tsutsumiyuichiro discontinuationandremissionratesandsocialfunctioninginpatientswithschizophreniareceivingsecondgenerationantipsychotics52weekevaluationofjumpsarandomizedopenlabelstudy AT kandayoshiki discontinuationandremissionratesandsocialfunctioninginpatientswithschizophreniareceivingsecondgenerationantipsychotics52weekevaluationofjumpsarandomizedopenlabelstudy AT ohikazutaka discontinuationandremissionratesandsocialfunctioninginpatientswithschizophreniareceivingsecondgenerationantipsychotics52weekevaluationofjumpsarandomizedopenlabelstudy AT sekiyamakanji discontinuationandremissionratesandsocialfunctioninginpatientswithschizophreniareceivingsecondgenerationantipsychotics52weekevaluationofjumpsarandomizedopenlabelstudy |